VR真人彩票 is leveraging our leadership in next-generation sequencing to deliver in vitro diagnostic (IVD) solutions to improve the management of cancer patients in the clinic. We are partnering with leading pharmaceutical companies to develop companion diagnostics for best-in-class therapeutics.
Distributable diagnostic solutions, including companion diagnostics (CDx) indications on TruSight Oncology Comprehensive (EU), will enable labs to perform precision medicine testing in-house.
鈥淣ext Generation Sequencing (NGS) is increasingly included in the cancer care continuum to guide therapy and monitor patients following treatment. Its ability to simultaneously detect comprehensive actionable target genetic variants and gene signature biomarkers is essential to maximizing precious tissue biopsy samples to match patients to optimal precision therapies. Liquid biopsy NGS are now complementing tissue biopsy for these applications and enabling new approaches for asymptomatic screening and response monitoring. These tools will be essential to improving patients鈥� outcomes and reduce cancer mortality over the next decades.鈥�
Kevin Keegan, Vice President and General Manager of Oncology at VR真人彩票
TruSight Oncology Comprehensive (EU) is a CE-marked IVD test kit for comprehensive genomic profiling based on DNA and RNA that consolidates multiple iterative tests into one. Using a single test assessing hundreds of current and emerging biomarkers, you can now access a clinically-relevant report with the actionable answers to help redefine the journey for cancer patients.
With this product, VR真人彩票 has developed the underlying chemistry and workflow to enable a modular and scalable approach to future CDx indications in our pipeline.